MEETING AGENDA

Emerging Data on the Role of Wnt Biology in Cancer

The Banbury Center, Cold Spring Harbor Laboratory, New York, USA
October 7-10, 2018

This meeting was funded by Leap Therapeutics

Lead Organizers:
Hans Clevers, Hubrecht Institute, Utrecht, Netherlands
Roeland Nusse, Stanford University, Stanford, USA
Bart Williams, Van Andel Research Institute, Michigan, USA

Supporting Organizers:
David Tuveson, Cold Spring Harbor Laboratory, New York, USA
Christopher Mirabelli, Leap Therapeutics, Cambridge, USA
Michael Kagey, Leap Therapeutics, Cambridge, USA

This Banbury Center meeting brought together experts in Wnt-related biology, immunology, pharmacology and translational cancer medicine in order to assess the current state of the science, identify emerging themes and prioritize potential therapeutic strategies.

SUNDAY, OCTOBER 7

Afternoon Participant arrivals
6:00 pm  Reception, dinner

MONDAY, OCTOBER 8

7:15 am  Breakfast
8:30 am  Welcome and Introductory Remarks  
Rebecca Leshan, The Banbury Center, Cold Spring Harbor Laboratory  
Roeland Nusse, Stanford University, Stanford, USA  
Bart Williams, Van Andel Research Institute, Michigan, USA  

8:50 am  SESSION 1: Therapeutic Targeting in Oncology  
Lawrence Lum, Pfizer, San Diego, USA  
David Virshup, Duke NUS Medical School, Singapore, Asia  
Marilyn Resh, Memorial Sloan Kettering Cancer Center, New York, USA  

10:50 am  SESSION 2: Regenerative Medicine Applications  
Luke Boulter, University of Edinburgh, Edinburgh, UK  
Yingzi Yang, Harvard School of Dental Medicine, Boston, USA  
Bart Williams, Van Andel Research Institute, Grand Rapids, USA  

12:15 pm  Luncheon  

2:00 pm  SESSION 3: Genetic Screens  
Stephane Angers, University of Toronto, Ontario, Canada  
Rajat Rohatgi, Stanford University School of Medicine, Stanford, USA  
Yashi Ahmed, Dartmouth Medical School, Hanover, USA  

3:45 pm  SESSION 4: Targeting DKK1  
Roberta Faccio, Washington University in St. Louis, USA  
Al Bothwell, Yale University School of Medicine, New Haven, USA  
David Wise, New York University Langone Medical Center, New York, USA  

5:00 pm  General Discussion, Day 1 Wrap-Up  

6:00 pm  Reception, dinner
TUESDAY, OCTOBER 9

7:15 am  Breakfast at Robertson House

8:30 am  [continued] SESSION 4: Targeting DKK1
          Walter Newman, Leap Therapeutics, Cambridge, USA
          Cyndi Sirard, Leap Therapeutics, Cambridge, USA
          Mike Kagey, Leap Therapeutics, Cambridge, USA

10:15 am SESSION 5: Membrane Receptors and Signalosome Assembly
          Christof Niehrs, German Cancer Research Center (DKFZ), Heidelberg, Germany
          Ethan Lee, Vanderbilt University, Nashville, USA
          Claudia Janda, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands

11:30 am General Discussion

12.30 pm Luncheon

2:00 pm SESSION 6: Modeling Receptors: R-Spondin, Rnf43/Znrf3, and Frizzleds
          Madelon Maurice, University Medical Center Utrecht, Netherlands
          Bruno Reversade, A*STAR Institute of Medical Biology, Immunos, Singapore
          Feng Cong, Novartis Institute for Biomedical Research, Cambridge, USA
          Austin Gurney, OncoMed Pharmaceuticals, Redwood City, USA

4:10 pm SESSION 7: Wnt Signaling and Stem Cells
          Xi He, Boston Children’s Hospital, Boston, USA
          Marian Waterman, University of California, Irvine, USA
          Rami Hannoush, Genentech, South San Francisco, USA

5:25 pm General Discussion, Day 2 Wrap-Up

6:00 pm Reception, dinner
WEDNESDAY, OCTOBER 10

7:15 am  Breakfast

9:00 am  SESSION 8: Emerging Applications for Wnt Signaling in Cancer
  Tuomas Tammela, Memorial Sloan Kettering Cancer Center, New York, USA
  Joan Massagué, Memorial Sloan Kettering Cancer Center, New York, USA
  Stefani Spranger, Koch Institute for Integrative Cancer Research, Cambridge, USA

9:50 am  General Discussion

10:45 am  SESSION 9: Wrap-Up: Conclusions and next Steps
  Roeland Nusse, Stanford University, Stanford, USA

12:15 pm  Luncheon

2:00 pm  Participant departures
MEETING PARTICIPANTS

Yashi Ahmed, Dartmouth Medical School
Stephane Angers, University of Toronto
Alfred Bothwell, Yale University School of Medicine
Luke Boulter, University of Edinburgh
Feng Cong, Novartis Institute for Biomedical Research
Roberta Faccio, Washington University in St. Louis
Austin Gurney, OncoMed Pharmaceuticals
Rami Hannoush, Genentech
Xi He, Boston Children’s Hospital
Claudia Janda, Princess Maxima Center for Pediatric Oncology
Michael Kagey, Leap Therapeutics
Ethan Lee, Vanderbilt University
Lawrence Lum, Pfizer
Joan Massagué, Memorial Sloan-Kettering Cancer Center
Madelon Maurice, University Medical Center Utrecht
Christopher Mirabelli, Leap Therapeutics
Walter Newman, Leap Therapeutics
Christof Niehrs, German Cancer Research Center (DKFZ)
Roeland Nusse, Stanford University
Sandeep Ravindran, science writer
Marilyn Resh, Memorial Sloan Kettering Cancer Center
Bruno Reversade, A*STAR Institute of Medical Biology
Rajat Rohatgi, Stanford University School of Medicine
Cynthia Sirard, Leap Therapeutics
Stefani Spranger, Koch Institute for Integrative Cancer Research
Tuomas Tammela, Memorial Sloan Kettering Cancer Center
David Tuveson, Cold Spring Harbor Laboratory
Harold Varmus, Weill Cornell Medicine
David Virshup, Duke-NUS Graduate Medical School
Marian Waterman, University of California Irvine
Bart Williams, Van Andel Research Institute
David Wise, New York University Langone Medical Center
Yingzi Yang, Harvard School of Dental Medicine